Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Identifieur interne : 002539 ( PubMed/Corpus ); précédent : 002538; suivant : 002540Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Auteurs : J. Bridgewater ; A. Lopes ; H. Wasan ; D. Malka ; L. Jensen ; T. Okusaka ; J. Knox ; D. Wagner ; D. Cunningham ; J. Shannon ; D. Goldstein ; M. Moehler ; T. Bekaii-Saab ; M G Mcnamara ; J W ValleSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2016.
English descriptors
- KwdEn :
- Bile Duct Neoplasms (diagnosis), Bile Duct Neoplasms (mortality), Bile Duct Neoplasms (therapy), Cholangiocarcinoma (diagnosis), Cholangiocarcinoma (mortality), Cholangiocarcinoma (therapy), Disease-Free Survival, Humans, Multivariate Analysis, Prognosis, Proportional Hazards Models, ROC Curve, Treatment Outcome.
- MESH :
- diagnosis : Bile Duct Neoplasms, Cholangiocarcinoma.
- mortality : Bile Duct Neoplasms, Cholangiocarcinoma.
- therapy : Bile Duct Neoplasms, Cholangiocarcinoma.
- Disease-Free Survival, Humans, Multivariate Analysis, Prognosis, Proportional Hazards Models, ROC Curve, Treatment Outcome.
Abstract
Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.
DOI: 10.1093/annonc/mdv483
PubMed: 26483051
Links to Exploration step
pubmed:26483051Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.</title><author><name sortKey="Bridgewater, J" sort="Bridgewater, J" uniqKey="Bridgewater J" first="J" last="Bridgewater">J. Bridgewater</name><affiliation><nlm:affiliation>UCL Cancer Institute, UCL, London j.bridgewater@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Lopes, A" sort="Lopes, A" uniqKey="Lopes A" first="A" last="Lopes">A. Lopes</name><affiliation><nlm:affiliation>UCL and CRUK Clinical Trials Centre, UCL, London.</nlm:affiliation></affiliation></author><author><name sortKey="Wasan, H" sort="Wasan, H" uniqKey="Wasan H" first="H" last="Wasan">H. Wasan</name><affiliation><nlm:affiliation>Department of Oncology, Imperial Healthcare, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Malka, D" sort="Malka, D" uniqKey="Malka D" first="D" last="Malka">D. Malka</name><affiliation><nlm:affiliation>Department of Cancer Medicine, Institute Gustave Roussy, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jensen, L" sort="Jensen, L" uniqKey="Jensen L" first="L" last="Jensen">L. Jensen</name><affiliation><nlm:affiliation>Department of Oncology, Vejle Hospital, Vejle, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Okusaka, T" sort="Okusaka, T" uniqKey="Okusaka T" first="T" last="Okusaka">T. Okusaka</name><affiliation><nlm:affiliation>Division of Hepatobiliary and Pancreatic Oncology, National Cancer Centre Hospital, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Knox, J" sort="Knox, J" uniqKey="Knox J" first="J" last="Knox">J. Knox</name><affiliation><nlm:affiliation>Department of Oncology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Wagner, D" sort="Wagner, D" uniqKey="Wagner D" first="D" last="Wagner">D. Wagner</name><affiliation><nlm:affiliation>Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Cunningham, D" sort="Cunningham, D" uniqKey="Cunningham D" first="D" last="Cunningham">D. Cunningham</name><affiliation><nlm:affiliation>Department of Medicine, Royal Marsden Hospital, Sutton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Shannon, J" sort="Shannon, J" uniqKey="Shannon J" first="J" last="Shannon">J. Shannon</name><affiliation><nlm:affiliation>Department of Oncology, Nepean Cancer Centre, Sydney.</nlm:affiliation></affiliation></author><author><name sortKey="Goldstein, D" sort="Goldstein, D" uniqKey="Goldstein D" first="D" last="Goldstein">D. Goldstein</name><affiliation><nlm:affiliation>Department of Oncology, Prince of Wales Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Moehler, M" sort="Moehler, M" uniqKey="Moehler M" first="M" last="Moehler">M. Moehler</name><affiliation><nlm:affiliation>Department of Internal Medicine, Johannes Gutenberg-University of Mainz, Mainz, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Bekaii Saab, T" sort="Bekaii Saab, T" uniqKey="Bekaii Saab T" first="T" last="Bekaii-Saab">T. Bekaii-Saab</name><affiliation><nlm:affiliation>Department of Oncology, The Ohio State University, Columbus, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mcnamara, M G" sort="Mcnamara, M G" uniqKey="Mcnamara M" first="M G" last="Mcnamara">M G Mcnamara</name><affiliation><nlm:affiliation>Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Valle, J W" sort="Valle, J W" uniqKey="Valle J" first="J W" last="Valle">J W Valle</name><affiliation><nlm:affiliation>Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26483051</idno><idno type="pmid">26483051</idno><idno type="doi">10.1093/annonc/mdv483</idno><idno type="wicri:Area/PubMed/Corpus">002539</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002539</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.</title><author><name sortKey="Bridgewater, J" sort="Bridgewater, J" uniqKey="Bridgewater J" first="J" last="Bridgewater">J. Bridgewater</name><affiliation><nlm:affiliation>UCL Cancer Institute, UCL, London j.bridgewater@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Lopes, A" sort="Lopes, A" uniqKey="Lopes A" first="A" last="Lopes">A. Lopes</name><affiliation><nlm:affiliation>UCL and CRUK Clinical Trials Centre, UCL, London.</nlm:affiliation></affiliation></author><author><name sortKey="Wasan, H" sort="Wasan, H" uniqKey="Wasan H" first="H" last="Wasan">H. Wasan</name><affiliation><nlm:affiliation>Department of Oncology, Imperial Healthcare, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Malka, D" sort="Malka, D" uniqKey="Malka D" first="D" last="Malka">D. Malka</name><affiliation><nlm:affiliation>Department of Cancer Medicine, Institute Gustave Roussy, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jensen, L" sort="Jensen, L" uniqKey="Jensen L" first="L" last="Jensen">L. Jensen</name><affiliation><nlm:affiliation>Department of Oncology, Vejle Hospital, Vejle, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Okusaka, T" sort="Okusaka, T" uniqKey="Okusaka T" first="T" last="Okusaka">T. Okusaka</name><affiliation><nlm:affiliation>Division of Hepatobiliary and Pancreatic Oncology, National Cancer Centre Hospital, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Knox, J" sort="Knox, J" uniqKey="Knox J" first="J" last="Knox">J. Knox</name><affiliation><nlm:affiliation>Department of Oncology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Wagner, D" sort="Wagner, D" uniqKey="Wagner D" first="D" last="Wagner">D. Wagner</name><affiliation><nlm:affiliation>Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Cunningham, D" sort="Cunningham, D" uniqKey="Cunningham D" first="D" last="Cunningham">D. Cunningham</name><affiliation><nlm:affiliation>Department of Medicine, Royal Marsden Hospital, Sutton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Shannon, J" sort="Shannon, J" uniqKey="Shannon J" first="J" last="Shannon">J. Shannon</name><affiliation><nlm:affiliation>Department of Oncology, Nepean Cancer Centre, Sydney.</nlm:affiliation></affiliation></author><author><name sortKey="Goldstein, D" sort="Goldstein, D" uniqKey="Goldstein D" first="D" last="Goldstein">D. Goldstein</name><affiliation><nlm:affiliation>Department of Oncology, Prince of Wales Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Moehler, M" sort="Moehler, M" uniqKey="Moehler M" first="M" last="Moehler">M. Moehler</name><affiliation><nlm:affiliation>Department of Internal Medicine, Johannes Gutenberg-University of Mainz, Mainz, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Bekaii Saab, T" sort="Bekaii Saab, T" uniqKey="Bekaii Saab T" first="T" last="Bekaii-Saab">T. Bekaii-Saab</name><affiliation><nlm:affiliation>Department of Oncology, The Ohio State University, Columbus, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mcnamara, M G" sort="Mcnamara, M G" uniqKey="Mcnamara M" first="M G" last="Mcnamara">M G Mcnamara</name><affiliation><nlm:affiliation>Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Valle, J W" sort="Valle, J W" uniqKey="Valle J" first="J W" last="Valle">J W Valle</name><affiliation><nlm:affiliation>Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bile Duct Neoplasms (diagnosis)</term><term>Bile Duct Neoplasms (mortality)</term><term>Bile Duct Neoplasms (therapy)</term><term>Cholangiocarcinoma (diagnosis)</term><term>Cholangiocarcinoma (mortality)</term><term>Cholangiocarcinoma (therapy)</term><term>Disease-Free Survival</term><term>Humans</term><term>Multivariate Analysis</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>ROC Curve</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Bile Duct Neoplasms</term><term>Cholangiocarcinoma</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Bile Duct Neoplasms</term><term>Cholangiocarcinoma</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Bile Duct Neoplasms</term><term>Cholangiocarcinoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease-Free Survival</term><term>Humans</term><term>Multivariate Analysis</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>ROC Curve</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26483051</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>19</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.</ArticleTitle><Pagination><MedlinePgn>134-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdv483</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using the independent international dataset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 410 patients were included from the ABC-02 study and 753 from the international dataset. An overall survival (OS) and progression-free survival (PFS) Cox model was derived from the ABC-02 study. White blood cells, haemoglobin, disease status, bilirubin, neutrophils, gender, and performance status were considered prognostic for survival (all with P < 0.10). Patients with metastatic disease {hazard ratio (HR) 1.56 [95% confidence interval (CI) 1.20-2.02]} and Eastern Cooperative Oncology Group performance status (ECOG PS) 2 had worse survival [HR 2.24 (95% CI 1.53-3.28)]. In a dataset restricted to patients who received cisplatin and gemcitabine with ECOG PS 0 and 1, only haemoglobin, disease status, bilirubin, and neutrophils were associated with PFS and OS. ROC analysis suggested the models generated from the ABC-02 study had a limited prognostic value [6-month PFS: area under the curve (AUC) 62% (95% CI 57-68); 1-year OS: AUC 64% (95% CI 58-69)].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data propose a set of prognostic criteria for outcome in advanced biliary tract cancer derived from the ABC-02 study that are validated in an international dataset. Although these findings establish the benchmark for the prognostic evaluation of patients with ABC and confirm the value of longheld clinical observations, the ability of the model to correctly predict prognosis is limited and needs to be improved through identification of additional clinical and molecular markers.</AbstractText><CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bridgewater</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UCL Cancer Institute, UCL, London j.bridgewater@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UCL and CRUK Clinical Trials Centre, UCL, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasan</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Imperial Healthcare, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malka</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cancer Medicine, Institute Gustave Roussy, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, Vejle Hospital, Vejle, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okusaka</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hepatobiliary and Pancreatic Oncology, National Cancer Centre Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knox</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Royal Marsden Hospital, Sutton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, Nepean Cancer Centre, Sydney.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Oncology, Prince of Wales Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moehler</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Johannes Gutenberg-University of Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekaii-Saab</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Ohio State University, Columbus, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>J W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Institute of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C444/A15953</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001650" MajorTopicYN="N">Bile Duct Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018281" MajorTopicYN="N">Cholangiocarcinoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABC-02</Keyword><Keyword MajorTopicYN="N">advanced disease</Keyword><Keyword MajorTopicYN="N">biliary tract cancer</Keyword><Keyword MajorTopicYN="N">cisplatin and gemcitabine</Keyword><Keyword MajorTopicYN="N">performance status</Keyword><Keyword MajorTopicYN="N">prognostic model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26483051</ArticleId><ArticleId IdType="pii">mdv483</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdv483</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002539 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002539 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26483051
|texte= Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26483051" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |